Prostate Cancer Medical Services in China

Prostate cancer is a malignant neoplasm originating in the prostate gland, predominantly affecting older men. It is among the most common non-cutaneous cancers globally, with incidence rising sharply after age 50. Risk factors include advancing age, family history, African ancestry, and certain genetic mutations (e.g., BRCA2). Clinical presentation varies—from asymptomatic detection via elevated serum prostate-specific antigen (PSA) and abnormal digital rectal examination to locally advanced disease causing urinary obstruction or metastatic symptoms such as bone pain. Diagnosis relies on multiparametric MRI, systematic and targeted transrectal ultrasound-guided biopsy, and genomic profiling where indicated. Staging integrates clinical assessment, imaging (e.g., PSMA-PET/CT), and pathological grading (Gleason score or Grade Group). Management is risk-stratified: active surveillance for low-risk disease; radical prostatectomy (open, laparoscopic, or robotic-assisted) or definitive radiotherapy (IMRT, SBRT, or brachytherapy) for intermediate- and high-risk localized cases; and multimodal systemic therapy—including androgen deprivation therapy (ADT), next-generation anti-androgens (e.g., enzalutamide), chemotherapy, and radioligand therapy (e.g., 177Lu-PSMA-617)—for recurrent or metastatic disease.

China offers compelling advantages for international patients seeking prostate cancer care. The country hosts nationally accredited oncology centers with internationally trained urologic oncologists and multidisciplinary tumor boards adhering to NCCN and EAU guidelines. Advanced technologies—including da Vinci Xi surgical systems, MR-guided focused ultrasound (MRgFUS), PSMA-PET/CT, and AI-enhanced radiation planning—are widely deployed in tier-1 hospitals. Five-year biochemical recurrence-free survival rates for localized disease exceed 90% in high-volume centers, supported by robust long-term follow-up data. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising clinical standards—making comprehensive care, including genomic testing and novel therapeutics, significantly more accessible.

As a dedicated medical tourism agency, we facilitate seamless access to this high-quality care: coordinating appointments with top-tier hospitals, providing transparent, all-inclusive pricing packages, arranging visa support, medical translation, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.

Treatment Options & Itemized Cost Breakdown: Prostate Cancer (Oncology Department)

Non-Surgical / Conservative / Medication Options

*Indicated for low-risk localized disease, elderly patients, or those unfit for surgery.*

• •Active Surveillance (PSA ≤10 ng/mL, Gleason ≤6, clinical stage T1c–T2a):

- Annual multiparametric MRI (3.0T): $280–$350 - Confirmatory biopsy (12-core transrectal ultrasound-guided): $190–$240

• •Androgen Deprivation Therapy (ADT) (for intermediate/high-risk localized or metastatic disease):

- Oral anti-androgen (bicalutamide 50 mg/day): $35–$55/month - Baseline + quarterly labs (PSA, testosterone, LFTs, CBC): $75–$95/test panel

Surgical / Procedural / Interventional Options

*Eligibility: Clinical stage ≤T3a, PSA <20 ng/mL, Gleason ≤8, no distant metastasis, ECOG PS 0–1.*

• •Radical Prostatectomy (robot-assisted or open):

- Surgery fee (including robotic platform use if applicable): $4,200–$6,100 - Hospital stay (7–10 days, including pathology, catheter care, antibiotics): $1,800–$2,400

• •External Beam Radiotherapy (EBRT) (IMRT/VMAT, 38–42 fractions):

- Fractionated treatment (per course): $3,900–$5,300 - Weekly on-treatment labs (CBC, renal panel): $45–$60/session

Special / Complex Condition Options

• •Metastatic Castration-Resistant Prostate Cancer (mCRPC):

- Docetaxel chemotherapy (6-cycle regimen, including premedication, infusion, monitoring): $2,700–$3,500/cycle - Lu-177-PSMA therapy (2–4 cycles, includes radiopharmaceutical, dosimetry, hospitalization): $8,900–$11,600/cycle

• •High-Risk Localized Disease (T3b/T4 or Gleason 9–10):

Quick Selection Guide

• •Age <65, low comorbidity burden, localized disease: Radical prostatectomy ($6,400–$9,100) — optimal cure potential and long-term cost control.
• •Age ≥75 or significant cardiovascular/pulmonary comorbidities: Active surveillance ($510–$750/year) or ADT monotherapy ($155–$215/month) — avoids procedural risk.
• •Intermediate-risk, budget-constrained (<$5,000): IMRT radiotherapy ($4,220–$5,710) — high local control, outpatient delivery.
• •Metastatic or mCRPC: Lu-177-PSMA ($8,900–$11,600/cycle) for PSMA-positive disease; docetaxel ($2,700–$3,500/cycle) if PSMA-negative or rapid progression.
• •High-risk localized with limited financial capacity: Neoadjuvant ADT + EBRT ($5,100–$6,200) — avoids surgery costs while maintaining oncologic efficacy.